Why a U.K. pharma giant is paying a 40% premium to pivot back to oncology
U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.
Sourcing & attribution. Newseze provides AI-curated summaries, narrative framing, and editorial analysis. The underlying reporting was contributed by MarketWatch Top; tap “Open original source” above to read their full reporting and support the contributing newsroom directly.
Related stories
Why it mattersECC wins $545m contract for Ghaf Woods’ Capria projects in Dubai
By Michael·1h ago
Why it mattersA direct Iranian military action threatens to unravel months of diplomatic efforts and raises immediate questions about whether the administration's ceasefire strategy can survive sustained regional hostilities.
Iran fired several rounds of missiles toward Israel, as President Donald Trump pushed to preserve a faltering ceasefire in the US’s 100-day conflict with Tehran…
By Marcus·1d ago
No comments yet. Be the first.